Dallmann I - Search Results

1

Interleukin-12 inhibits apoptosis in chronic lymphatic leukemia (CLL) B cells.

Schuhknecht S, Duensing S, Dallmann I, Grosse J, Reitz M, Atzpodien J. Schuhknecht S, et al. Among authors: dallmann i. Cancer Biother Radiopharm. 2002 Oct;17(5):495-9. doi: 10.1089/108497802760804718. Cancer Biother Radiopharm. 2002. PMID: 12470418

2

In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.

Meffert M, Hanninen EL, Menzel T, Schomburg A, Duensing S, Dallmann I, Grosse J, Vocke S, Buer J, Deckert M, et al. Meffert M, et al. Among authors: dallmann i. Cancer Biother. 1994 Winter;9(4):307-16. doi: 10.1089/cbr.1994.9.307. Cancer Biother. 1994. PMID: 7719378 Clinical Trial.

3

Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus.

Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Zorn U, et al. Among authors: dallmann i. Cancer Biother. 1994 Fall;9(3):225-35. doi: 10.1089/cbr.1994.9.225. Cancer Biother. 1994. PMID: 7820184

4

Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma.

Buer J, Probst M, Duensing S, Köditz H, Franzke A, Dallmann I, Ganser A, Atzpodien J. Buer J, et al. Among authors: dallmann i. Cancer Biother Radiopharm. 1997 Jun;12(3):143-7. doi: 10.1089/cbr.1997.12.143. Cancer Biother Radiopharm. 1997. PMID: 10851460

5

13cis- and all-trans retinoic acid have antiproliferative effects on CML cells and render IFN alpha antiproliferative potency after combined treatment in vitro.

Benthin M, Dallmann I, Atzpodien J. Benthin M, et al. Among authors: dallmann i. Cancer Biother Radiopharm. 2001 Aug;16(4):323-31. doi: 10.1089/108497801753131408. Cancer Biother Radiopharm. 2001. PMID: 11603003

6

Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma.

Buentig N, Stoerkel S, Richter E, Dallmann I, Reitz M, Atzpodien J. Buentig N, et al. Among authors: dallmann i. Cancer Biother Radiopharm. 2004 Jun;19(3):331-42. doi: 10.1089/1084978041425007. Cancer Biother Radiopharm. 2004. PMID: 15285879

7

Diminished expression of interleukin-2 receptors in vivo after prior chemotherapy in advanced cancer patients receiving recombinant interleukin-2.

Atzpodien J, Körfer A, Hadam M, Schomburg A, Menzel T, Dallmann I, Poliwoda H, Kirchner H. Atzpodien J, et al. Among authors: dallmann i. Mol Biother. 1991 Jun;3(2):60-2. Mol Biother. 1991. PMID: 1910621

8

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.

Hänninen EL, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J. Hänninen EL, et al. Among authors: dallmann i. Cancer Res. 1991 Dec 1;51(23 Pt 1):6312-6. Cancer Res. 1991. PMID: 1933892

9

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.

Atzpodien J, Körfer A, Evers P, Franks CR, Knüver-Hopf J, Lopez-Hänninen E, Fischer M, Mohr H, Dallmann I, Hadam M, et al. Atzpodien J, et al. Among authors: dallmann i. Mol Biother. 1990 Mar;2(1):18-26. Mol Biother. 1990. PMID: 2334534

10

In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.

Meffert M, Schomburg A, Hänninen EL, Menzel T, Vocke S, Dallmann I, Grosse J, Duensing S, Buer J, Kirchner H, et al. Meffert M, et al. Among authors: dallmann i. Anticancer Res. 1995 Jan-Feb;15(1):127-32. Anticancer Res. 1995. PMID: 7733621

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters